Montefiore Einstein Comprehensive Cancer Center | Strategic Alliance Partners

December 11, 2023

Drs Donington and Stiles discuss how the findings from the ADAURA trial with adjuvant osimertinib have changed thoracic surgery expectations, the potential surgical implications of the ALINA trial with adjuvant alectinib, and the importance of early-stage molecular testing in lung cancer.

November 16, 2023

Dr Halmos discusses the ongoing investigation of the potent, selective, and irreversible EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.

October 15, 2023

Montefiore Einstein Comprehensive Cancer Center opened a new state-of-the-art breast center at the Hutchinson Metro Center at 1250 Waters Place.

October 09, 2023

Beth N. McLellan, MD, discusses the use of a low-cost, topical treatment to prevent severe cases of acute radiation dermatitis potentially caused by the skin bacterium Staphylococcus aureus in breast cancer.

September 20, 2023

The newly renamed Montefiore Einstein Comprehensive Cancer Center has been awarded comprehensive designation by the National Cancer Institute of the National Institutes of Health, the ultimate standard achieved by only 55 other NCI cancer centers in the U.S.

September 20, 2023

As oncogene-driven therapies move into clinical practice, it is paramount that clinicians have the tools and understanding to integrate the latest evidence for the appropriate treatment of patients with lung cancer.

August 08, 2023

Balazs Halmos, MD, explains why a national effort is needed to mitigate current and future drug shortages in oncology and discusses strategies being used to navigate the current cisplatin and carboplatin shortages.

June 02, 2023

Closing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.

May 26, 2023

A brief review of the POSEIDON trial, which analyzed durvalumab with or without tremelimumab in combination with chemotherapy in advanced NSCLC.

May 26, 2023

Key opinion leaders in the field of non–small cell lung cancer management discuss the role of immunotherapy in patients with concomitant KRAS and KEAP1/STK11 mutations.

May 19, 2023

A comprehensive discussion on combination chemotherapy + immunotherapy regimens available to patients with advanced non–small cell lung cancer.

May 19, 2023

Shared insight on the value that molecular testing and PD-L1 testing, respectively, have on determining optimal therapy for patients with advanced non–small cell lung cancer.

May 12, 2023

Switching their focus to advanced non–small cell lung cancer, panelists identify parameters that may influence the use of immune checkpoint inhibitors in this setting.

May 05, 2023

Switching their focus to the adjuvant setting of resectable NSCLC, expert panelists identify treatment options in this setting and review the clinical data behind them.

May 05, 2023

Shared insight from key opinion leaders on the value of molecular testing in patients with resectable non–small cell lung cancer and how it can be applied.

April 28, 2023

Expert oncologists reflect on key factors that aid in the selection of therapy for patients diagnosed with resectable non–small cell lung cancer (NSCLC).

March 22, 2023

Although the first FDA approval for CAR T-cell therapy in multiple myeloma was 2 years ago, unfortunately, the treatment remains out of reach for too many patients.

December 06, 2022

Tumor microenvironment of metastasis doorway density—a biomarker of distant metastatic recurrence—is higher in Black women vs White women with estrogen receptor–positive/HER2-negative breast cancer who have residual disease after neoadjuvant chemotherapy.

December 01, 2022

Montefiore Einstein Cancer Center hopes to begin combating systemic inequities and improve cancer outcomes for historically disadvantaged populations by taking a data-driven approach to delivering neoadjuvant therapy in communities that are economically and socially marginalized.

November 25, 2022

Balazs Halmos, MD, discusses the role of immunotherapy in the frontline setting of NSCLC and the emerging pipeline of antibody-drug conjugates that could affect the treatment paradigm in lung cancer.